Miguel Sieler named C.E.O of Neovacs
NEOVACS annonced that Miguel Sieler, former Chairman and Chief Executive Officer of Bayer France has been named Chief Executive Officer of Neovacs, replacing Guy-Charles Fanneau De La Horie.
Miguel Sieler will pursue the development of Neovacs and put a particular focus on the value of its pipeline. Neovacs is currently concentrating its R&D efforts on two immunotherapies in three severe indications : TNF-Kinoid in RA and Crohn’s Disease and IFNα-Kinoid in Lupus.
Miguel Sieler joined Bayer AG in 1975 for an international career which started at the group headquarters in Germany. He served in various senior management positions in Brussels and Sao Paulo before becoming President of Bayer in Korea, followed by 4 years as C.E.O of Bayer Pharma France. In 1998, Miguel Sieler became Chairman and CEO of the Bayer Group in France until his retirement in 2008. Miguel Sieler is also member of the Board of Nexity S.A. and Chairman of Wittycell, a French biotechnology company dedicated to the development of innovative vaccine adjuvants. Mr. Sieler holds a Master in Law degree from the University of Tubingen, Germany and graduated from the Institut d’Etudes Politiques de Paris, France.
Other news from the department people
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
